Skip to main content

Table 1 HAI and NAI Titer Plus Previous Vaccination Data for the Year-4 FLUVACS Study ∗

From: HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy

   

HAI Titers

NAI Titers

Treatment

Group

No.

No. w/ Day 0 and Day 30

No. w/ Day 0 and Day 30

Placebo

Total

325

125

92

 

Cases

30

30

29

 

Controls

295

95

63

LAIV

Total

814

324

227

 

Cases

54

54

52

 

Controls

760

270

175

IIV

Total

813

279

178

 

Cases

22

22

22

 

Controls

791

257

156

Placebo

Total

136

48

42

Restrict

Cases

15

15

15

EVERVAX=1 ∗∗

Controls

121

33

27

LAIV

Total

307

135

92

Restrict

Cases

26

26

24

EVERVAX=1

Controls

281

109

68

IIV

Total

288

99

58

Restrict

Cases

6

6

6

EVERVAX=1

Controls

282

93

52

Placebo

Total

138

54

35

Restrict

Cases

11

11

10

EVERVAX=0

Controls

127

43

25

LAIV

Total

388

144

105

Restrict

Cases

21

21

21

EVERVAX=0

Controls

367

123

84

IIV

Total

388

128

93

Restrict

Cases

13

13

13

EVERVAX=0

Controls

375

115

80

  1. ∗In the third column, all participants with an observed influenza endpoint (Cases) and all participants completing follow-up (with a post-season sample) without experiencing the influenza endpoint (Controls) are included in the counts, regardless of whether immunological data were measured. The remaining columns include the subset of these participants with HAI or NAI titer measurements at Day 0 and Day 30. For each assay HAI and NAI, all participants either had both Day 0 and Day 30 titers measured, or neither Day 0 and Day 30 titers measured. All participants with NAI titers measured also had HAI titers measured. ∗∗EVERVAX is self-report of ever having received a previous flu vaccine: 1 = yes, 0 = no